<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00122447</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00000749</org_study_id>
    <secondary_id>UL1RR025008</secondary_id>
    <secondary_id>Sankyo CS-866</secondary_id>
    <secondary_id>1K23DK070715-01A1</secondary_id>
    <nct_id>NCT00122447</nct_id>
  </id_info>
  <brief_title>Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance</brief_title>
  <official_title>CVD Risk and Prevention in Early Glucose Intolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers,
      Î²-cell function, and insulin sensitivity can be improved by targeting mechanisms of both
      diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an
      anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized,
      controlled trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes is a common, major health problem in the United States, and it significantly
      increases the risk of developing heart disease, which is the leading cause of death. Research
      studies have shown that the risk of heart disease is increased, even in the &quot;pre-diabetes&quot; or
      impaired glucose tolerance (IGT) stage, before the onset of true diabetes. While many studies
      have shown that aggressive management of diabetes lowers the risk of heart disease, at the
      present time, it is not known how best to treat patients with impaired glucose tolerance
      (pre-diabetes) to prevent the development of heart disease. It is also not known where in the
      range of blood sugar levels risk begins to increase. The purpose of this study is to
      determine:

        -  whether medications, which target pathways involved in the development of heart disease,
           can decrease the risk of heart disease in individuals with impaired glucose tolerance;
           and

        -  whether a &quot;high&quot; blood sugar level measured one hour after drinking a standard
           high-sugar drink is associated with an increased risk of heart disease even in
           individuals who have no evidence of diabetes or pre-diabetes.

      The purpose of Aim 1 of this study is to determine whether medications, which target pathways
      involved in the development of heart disease, can decrease the risk of heart disease in
      individuals with impaired glucose tolerance. One hundred-twenty volunteers with impaired
      glucose tolerance and 30 volunteers with normal glucose tolerance (normal blood sugars after
      ingesting a standard high-sugar drink) will be recruited from the &quot;Screening for Impaired
      Glucose Tolerance&quot; (SIGT) study. The 30 volunteers with normal glucose tolerance will not
      take any study medication, but will undergo medical testing to determine their risk of heart
      disease at the beginning of the study, after which their participation in the study will be
      complete. The 120 volunteers with impaired glucose tolerance will be randomly assigned to one
      of four medications to be taken over a one-year period:

        -  alpha lipoic acid (an antioxidant, dietary supplement);

        -  olmesartan (a drug used to treat high blood pressure);

        -  aspirin (an anti-inflammatory drug); and

        -  placebo (an inactive, &quot;dummy&quot; pill).

      Subjects with impaired glucose tolerance will undergo medical testing to determine their risk
      of heart disease at the beginning of the study (before beginning study medications), after 3
      months of intervention, and again at the end of the study (12 months after enrollment). Test
      results will be compared between the subjects taking each of the active medications and those
      taking placebo, to determine if the medications lead to a significant reduction in the risk
      for the development of heart disease. The medical tests used in this study are currently used
      in medical practice, and include blood and urine specimens, ultrasound testing of the artery
      at the arm, and an insulin sensitivity test (test of how effectively the body uses sugar).
      All visits and tests will be conducted in the General Clinical Research Centers of Emory
      University Hospital and Grady Memorial Hospital.

      The purpose of Aim 2 of this study is to determine whether a &quot;high&quot; blood sugar level
      measured one hour after drinking a standard high-sugar drink (1-hour blood sugar level) is
      associated with an increased risk of heart disease even in individuals who have no evidence
      of diabetes or pre-diabetes. Seventy-five volunteers with normal glucose tolerance (normal
      blood sugars after ingesting a standard high-sugar drink) will be recruited from the SIGT
      study, as well as 15 subjects with impaired glucose tolerance and 15 with diabetes. The
      subjects with normal glucose tolerance will be grouped into those with &quot;low&quot;, &quot;middle&quot;, and
      &quot;high&quot; 1-hour blood sugar levels. All subjects will undergo medical testing (as in Aim 1
      above) to determine their risk of heart disease. Test results of subjects with &quot;low&quot;,
      &quot;middle&quot;, and &quot;high&quot; 1-hour blood sugar levels will be compared against one another, as well
      as against those of subjects with IGT and diabetes. If subjects with normal glucose tolerance
      but &quot;high&quot; 1-hour blood sugar levels are found to have increased risk for heart disease
      compared to those with &quot;low&quot; 1-hour blood sugar levels, then the 1-hour blood sugar levels
      may provide important information regarding an increased risk of heart disease even in
      individuals with normal glucose tolerance but &quot;high&quot; 1-hour blood sugar levels - a population
      which otherwise would not be identified with the current standard tests used for the
      diagnosis of diabetes and pre-diabetes.

      Over 40 million Americans have pre-diabetes (impaired glucose tolerance), which is associated
      with an increased risk of the development of both diabetes and heart disease. Findings from
      these studies will provide important insights into the pathways that lead to the development
      of heart disease related to pre-diabetes, prevention of heart disease in the pre-diabetic
      population, and identification of individuals at high risk for heart disease earlier in their
      natural history - even before the onset of pre-diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AIM 1: Change in Flow Mediated Dilation (FMD) (%)</measure>
    <time_frame>12 months of intervention</time_frame>
    <description>Surrogate measure of endothelial function defined as the percent change in dilation of the brachial artery after cuff compression of arm compared to before cuff compression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AIM 1: Change in hsCRP (High Sensitivity C-reactive Peptide) Level</measure>
    <time_frame>12 months of intervention</time_frame>
    <description>Inflammatory marker</description>
  </secondary_outcome>
  <other_outcome>
    <measure>AIM 2: Difference in FMD (Measure of Endothelial Function)</measure>
    <time_frame>Cross-sectional</time_frame>
    <description>Comparison of FMD (measure of endothelial function) between NGT, IGT and diabetes at baseline. FMD is a surrogate measure of endothelial function defined as the percent change in dilation of the brachial artery after cuff compression of arm compared to before cuff compression.
No analysis was conducted due to under-recruitment.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Impaired Glucose Tolerance</condition>
  <condition>Prediabetic State</condition>
  <arm_group>
    <arm_group_label>Anti-inflammatory agent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin (ASA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angiotensin receptor blocker (ARB)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Olmesartan (ARB)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antioxidant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alpha lipoic acid (ALA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Aspirin placebo once a day Olmesartan placebo once a day Alpha lipoic acid placebo twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>325 mg PO QD</description>
    <arm_group_label>Anti-inflammatory agent</arm_group_label>
    <other_name>Bayer aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpha lipoic acid</intervention_name>
    <description>600 mg PO BID</description>
    <arm_group_label>Antioxidant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan</intervention_name>
    <description>40 mg PO QD</description>
    <arm_group_label>Angiotensin receptor blocker (ARB)</arm_group_label>
    <other_name>Benicar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical placebo for each active comparator:
placebo aspirin 325 mg PO QD; placebo for alpha lipoic acid 600 mg PO BID; placebo for olmesartan 40 mg PO QD</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Impaired glucose tolerance

        Exclusion Criteria:

          -  Diagnosis of diabetes

          -  Taking an ACE inhibitor (ACE-I), angiotensin II receptor blocker (ARB), or aspirin

          -  Have systolic blood pressure &gt;140 mm Hg

          -  Have a chronic inflammatory disorder (i.e. rheumatoid arthritis, inflammatory bowel
             disease, sinusitis)

          -  Vascular disease (cardiac, peripheral, cerebral)

          -  Renal insufficiency or hepatic abnormalities

          -  Gastrointestinal bleeding (defined as gastric or duodenal ulcer, hematemesis, and/or
             blood in the stool) or significant other upper gastrointestinal problems (i.e.
             gastritis) within the previous 6 months

          -  Anemia or a history of bleeding disorder

          -  Have a history of ARB or aspirin allergy

          -  Have the syndrome of asthma, rhinitis, and nasal polyps

          -  Have other medical problems which would preclude taking potential study medications
             for 12 months

          -  Are pregnant or have a positive pregnancy test

          -  Are breast feeding

          -  Are unable or unwilling to tolerate having one catheter in each arm for 4 hours

          -  Have health status such that the envisioned blood sampling would confer a physiologic
             risk

          -  Have other physical, social, or behavioral problems which would decrease the
             likelihood that they would remain in the study for 12 months

          -  Do not appear capable of giving informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary K Rhee, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Health System</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2005</study_first_submitted>
  <study_first_submitted_qc>July 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2005</study_first_posted>
  <results_first_submitted>May 18, 2012</results_first_submitted>
  <results_first_submitted_qc>May 18, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 20, 2012</results_first_posted>
  <last_update_submitted>November 12, 2013</last_update_submitted>
  <last_update_submitted_qc>November 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Dr. Mary Rhee</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Prediabetic state</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Glucose intolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
    <mesh_term>Thioctic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>266 subjects with IGT were contacted: 121 refused, 63 ineligible, 84 screened/enrolled.
Among the 84 enrolled subjects:
1 was withdrawn, 13 dropped out before randomization, 70 were randomized (17 alpha lipoic acid, 18 aspirin, 18 olmesartan, 17 placebo).
After randomization, 10 dropped out, and 3 were withdrawn.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Aspirin (ASA) 325 mg PO Once Daily</title>
          <description>Anti-inflammatory agent</description>
        </group>
        <group group_id="P2">
          <title>Olmesartan (ARB) 40 mg PO Once Daily</title>
          <description>Angiotensin receptor blocker (ARB)</description>
        </group>
        <group group_id="P3">
          <title>Alpha Lipoic Acid (ALA) 600 mg PO Twice Daily</title>
          <description>Antioxidant</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Aspirin placebo PO once a day Olmesartan placebo PO once a day Alpha lipoic acid placebo PO twice a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aspirin (ASA) 325 mg PO Once Daily</title>
          <description>Anti-inflammatory agent</description>
        </group>
        <group group_id="B2">
          <title>Olmesartan (ARB) 40 mg PO Once Daily</title>
          <description>Angiotensin receptor blocker (ARB)</description>
        </group>
        <group group_id="B3">
          <title>Alpha Lipoic Acid (ALA) 600 mg PO Twice Daily</title>
          <description>Antioxidant</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Aspirin placebo PO once a day Olmesartan placebo PO once a day Alpha lipoic acid placebo PO twice a day</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="17"/>
            <count group_id="B4" value="17"/>
            <count group_id="B5" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.4" spread="12.8"/>
                    <measurement group_id="B2" value="55.2" spread="8.5"/>
                    <measurement group_id="B3" value="52.4" spread="7.0"/>
                    <measurement group_id="B4" value="51.3" spread="11.7"/>
                    <measurement group_id="B5" value="52.6" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>AIM 1: Change in hsCRP (High Sensitivity C-reactive Peptide) Level</title>
        <description>Inflammatory marker</description>
        <time_frame>12 months of intervention</time_frame>
        <population>Based on the number of subjects who completed 12 months of intervention and testing</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin (ASA) 325 mg PO Once Daily</title>
            <description>Anti-inflammatory agent</description>
          </group>
          <group group_id="O2">
            <title>Olmesartan (ARB) 40 mg PO Once Daily</title>
            <description>Angiotensin receptor blocker (ARB)</description>
          </group>
          <group group_id="O3">
            <title>Alpha Lipoic Acid (ALA) 600 mg PO Twice Daily</title>
            <description>Antioxidant</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Aspirin placebo PO once a day Olmesartan placebo PO once a day Alpha lipoic acid placebo PO twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>AIM 1: Change in hsCRP (High Sensitivity C-reactive Peptide) Level</title>
          <description>Inflammatory marker</description>
          <population>Based on the number of subjects who completed 12 months of intervention and testing</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.27" spread="0.86"/>
                    <measurement group_id="O2" value="-2.34" spread="1.1"/>
                    <measurement group_id="O3" value="0.23" spread="0.70"/>
                    <measurement group_id="O4" value="0.32" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.449</p_value>
            <p_value_desc>Association between treatment arm, compared to placebo, on change in hsCRP from baseline to 12 months of intervention, adjusted for age, sex, and race.</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-0.941</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.229</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.435</ci_lower_limit>
            <ci_upper_limit>1.552</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <p_value_desc>Association between treatment arm, compared to placebo, on change in hsCRP from baseline to 12 months of intervention, adjusted for age, sex, and race.</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-2.677</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.211</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.133</ci_lower_limit>
            <ci_upper_limit>-0.221</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.943</p_value>
            <p_value_desc>Association between treatment arm, compared to placebo, on change in hsCRP from baseline to 12 months of intervention, adjusted for age, sex, and race.</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>0.088</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.210</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.367</ci_lower_limit>
            <ci_upper_limit>2.542</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AIM 1: Change in Flow Mediated Dilation (FMD) (%)</title>
        <description>Surrogate measure of endothelial function defined as the percent change in dilation of the brachial artery after cuff compression of arm compared to before cuff compression</description>
        <time_frame>12 months of intervention</time_frame>
        <population>Based on the number of subjects who completed 12 months of intervention and testing</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin (ASA) 325 mg PO Once Daily</title>
            <description>Anti-inflammatory agent</description>
          </group>
          <group group_id="O2">
            <title>Olmesartan (ARB) 40 mg PO Once Daily</title>
            <description>Angiotensin receptor blocker (ARB)</description>
          </group>
          <group group_id="O3">
            <title>Alpha Lipoic Acid (ALA) 600 mg PO Twice Daily</title>
            <description>Antioxidant</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Aspirin placebo PO once a day Olmesartan placebo PO once a day Alpha lipoic acid placebo PO twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>AIM 1: Change in Flow Mediated Dilation (FMD) (%)</title>
          <description>Surrogate measure of endothelial function defined as the percent change in dilation of the brachial artery after cuff compression of arm compared to before cuff compression</description>
          <population>Based on the number of subjects who completed 12 months of intervention and testing</population>
          <units>percentage of arterial dilation change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0012" spread="0.030"/>
                    <measurement group_id="O2" value="0.018" spread="0.032"/>
                    <measurement group_id="O3" value="0.014" spread="0.034"/>
                    <measurement group_id="O4" value="0.0053" spread="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: no difference between active treatment group compared to placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.943</p_value>
            <p_value_desc>Association between treatment arm, compared to placebo, on change in FMD from baseline to 12 months of intervention, adjusted for age, sex, race, and LDL-cholesterol.</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-0.001</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.025</ci_lower_limit>
            <ci_upper_limit>0.023</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.280</p_value>
            <p_value_desc>Association between treatment arm, compared to placebo, on change in FMD from baseline to 12 months of intervention, adjusted for age, sex, race, and LDL-cholesterol.</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>0.014</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.012</ci_lower_limit>
            <ci_upper_limit>0.039</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.313</p_value>
            <p_value_desc>Association between treatment arm, compared to placebo, on change in FMD from baseline to 12 months of intervention, adjusted for age, sex, race, and LDL-cholesterol.</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>0.012</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.012</ci_lower_limit>
            <ci_upper_limit>0.037</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>AIM 2: Difference in FMD (Measure of Endothelial Function)</title>
        <description>Comparison of FMD (measure of endothelial function) between NGT, IGT and diabetes at baseline. FMD is a surrogate measure of endothelial function defined as the percent change in dilation of the brachial artery after cuff compression of arm compared to before cuff compression.
No analysis was conducted due to under-recruitment.</description>
        <time_frame>Cross-sectional</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Glucose Tolerance (NGT)</title>
            <description>Normal fasting glucose (&lt;100 mg/dl) and normal 2-hr glucose level (&lt;140 mg/dl) after 75g OGTT</description>
          </group>
          <group group_id="O2">
            <title>Impaired Glucose Tolerance (IGT)</title>
            <description>After 75g OGTT:
Fasting glucose &lt;126 mg/dl and 2-hr glucose level 140-199 mg/dl</description>
          </group>
          <group group_id="O3">
            <title>Diabetes</title>
            <description>After 75g OGTT:
Fasting glucose &gt;=126 mg/dl and 2-hr glucose level &gt;=200 mg/dl</description>
          </group>
        </group_list>
        <measure>
          <title>AIM 2: Difference in FMD (Measure of Endothelial Function)</title>
          <description>Comparison of FMD (measure of endothelial function) between NGT, IGT and diabetes at baseline. FMD is a surrogate measure of endothelial function defined as the percent change in dilation of the brachial artery after cuff compression of arm compared to before cuff compression.
No analysis was conducted due to under-recruitment.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aspirin</title>
          <description>Anti-inflammatory agent</description>
        </group>
        <group group_id="E2">
          <title>Olmesartan</title>
          <description>Angiotensin receptor blocker (ARB)</description>
        </group>
        <group group_id="E3">
          <title>Alpha Lipoic Acid</title>
          <description>Antioxidant</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Aspirin placebo once a day Olmesartan placebo once a day Alpha lipoic acid placebo twice a day</description>
        </group>
        <group group_id="E5">
          <title>Enrolled, But Not Yet Randomized</title>
          <description>Enrolled into study, but not yet randomized to study medication</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <description>Pt was diagnosed with pancreatic cancer soon after enrollment, but before randomization to intervention group.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Reaction to nitroglycerin during FMD test</sub_title>
                <description>During baseline FMD testing, prior to actually starting study medication, a vasavagal response to NTG was developed.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Not fully powered due to under-enrollment and high drop-out rate. Higher than anticipated precision error of FMD measures. Possible Hawthorne effect with lifestyle changes. Short treatment period relative to long-term CVD risk in prediabetes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mary Rhee, M.D.</name_or_title>
      <organization>Emory University School of Medicine</organization>
      <phone>404-778-1660</phone>
      <email>mrhee@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

